There's one less antibody player on the market now that Bristol-Myers Squibb Co. has staked a claim to Medarex Inc. in the form of a $2.4 billion buyout offer, leaving many to speculate on the next takeout target in the rapidly diminishing antibody platform space. (BioWorld Today) Read More
